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slag, 2006), neurocognitive functioning (COG scale) (Macken-
zie, 2002), and Beck Depression Inventory (Findler, 2001).
CONCLUSION: There is evidence to suggest that the PF Scale
of the SF-36 is reliable, as measured by internal consistency, and
valid, as measured by discriminant and concurrent validity.
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SYSTEMIC TREATMENT OF MODERATE TO SEVERE PSORIASIS
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OBJECTIVES: New BA offer more therapeutic options to
control psoriasis symptoms but add to the already considerable
cost of managing psoriasis. Expert panels have published guide-
lines for the use of BA although few of them considered the treat-
ment options cost-effectiveness. The Brazilian expert guidelines,
however, considered. We present a Brazilian cost effectiveness
model based on micro-simulation. METHODS: Our cost effec-
tiveness model simulates the real-life Brazilian treatment
sequence (acitretin, methotrexate, cyclosporine, BA) for 1000
patients based on the average time of use of each drug (10.74,
6.56, 24.00, and 30.00 months, respectively). Three different
BA, adalimumab, eternacept and inﬂiximab, were analyzed. Cost
effectiveness was calculated in terms of the number of patients
that achieve PASI 75 response with each BA. The base case was
a moderate-to-severe psoriasis patient, with at least 10% BSA
affected, PASI score of at least 12, without infection in the lesions
and eligible for systemic therapy. Time of use of each drug in
Brazil came from a previous Brazilian study and the PASI score
from major studies with each drug from the medical literature.
The local disease management and costs were based on a Delphi
panel according to the private health care perspective. Outcomes
were discounted at 3% annually. RESULTS: In order that all
patients pass all the four treatment lines it took an average time
of 71.3 months; the Brazilian treatment sequence added to fort-
nightly adalimumab, weekly adalimumab, inﬂiximab and eter-
nacept, respectively, generated 529, 799, 879 and 490 patients
achieving PASI 75 and also, respectively, generated R$
129,071,880.38, R$ 257,708,724.48, R$ 132,251,142.76, R$
342,274,532.45 total costs. CONCLUSION: The Brazilian
treatment sequence added to inﬂiximab is a dominant alterna-
tive in relation to that added to weekly adalimumab and eter-
nacept. It also has an acceptable cost-effectiveness ratio in Brazil
in relation to fortnightly adalimumab (R$9092.70).
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OBJECTIVES: To determine the incremental direct health care
and indirect work loss costs associated with patients diagnosed
with atopic dermatitis (AD) from an employer-payer perspective.
METHODS: A de-identiﬁed claims database consisting of 5.1
million covered lives from 31 Fortune 500 self-insured employ-
ers over the period 1998–2005 was used. Each AD patient was
matched with three controls based on age and gender. The
average monthly direct health care costs (i.e., medical & phar-
maceutical costs) were computed for the respective groups. For
the subset of patients who were active employees, the indirect
costs of lost work time were calculated for each group, as mea-
sured by employer disability payments and sick leave time 
multiplied by the employee’s wage. In addition, a multivariate
two-part regression was used to isolate the cost increase attrib-
utable to AD by controlling for age, gender, year, comorbidities,
and organ transplantation. RESULTS: The univariate analysis
showed that the AD patients (N = 13,749) were associated with
higher medical and pharmacy costs than the control group (N =
41,247) by an average of $47 and $42 per person per month,
respectively (medical: $270 vs. $223, p < 0.003; pharmacy: $80
vs. $38, p < 0.0001), bringing the total increase in health care
costs to $88 per person per month ($349 vs. $261, p < 0.0001).
In the subset of active employees, the AD group (N = 1588) was
associated with higher indirect work loss costs of $64 per person
per month ($148 vs. $85, p < 0.0001) than the control group (N
= 3900). For each cost category, a statistically signiﬁcant cost
increase for AD patients was conﬁrmed through the multivari-
ate analysis (adjusted incremental direct cost = $52, p < 0.0001;
adjusted incremental indirect cost = $31, p < 0.0001). CON-
CLUSION: AD was associated with a statistically signiﬁcant
increase in health care and work loss costs. The multivariate
analysis indicated that the total direct and indirect cost increase
was approximately $83 per person per month.
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OBJECTIVES: To determine the incremental direct health care
and indirect work loss costs experienced by employer-payers for
patients diagnosed with seborrheic dermatitis (SD). METHODS:
A de-identiﬁed claims database consisting of 5.1 million covered
lives from 31 Fortune 500 self-insured employers over the period
1998–2005 was used. Each SD patient was matched with three
controls based on age and gender. The average monthly direct
health care costs (i.e., medical & pharmaceutical costs) were
computed for the respective groups. For the subset of patients
who were active employees, the indirect costs of lost work time
were calculated for each group, as measured by employer dis-
ability payments and sick leave time multiplied by the employee’s
wage. In addition, a multivariate two-part regression was used
to isolate the cost increase attributable to SD by controlling for
age, gender, year, comorbidities, and organ transplantation.
RESULTS: The univariate analysis showed that the SD patients
(N = 6860) were associated with higher medical and pharmacy
costs than the control group (N = 20,580) by an average of $136
and $62 per person per month, respectively (medical: $412 vs.
$277, p < 0.0001; pharmacy: $139 vs. $76, p < 0.0001), bring-
ing the total increase in health care costs to $198 per person per
month ($551 vs. $353, p < 0.0001). In the subset of active
employees, the SD group (N = 1666) was associated with a
higher indirect work loss cost of $50 per person per month ($132
vs. $82, p < 0.0001) than the control group (N = 4103). For each
cost category, a statistically signiﬁcant cost increase for SD
patients was conﬁrmed through the multivariate analysis
(adjusted incremental direct cost = $62, p = 0.005; adjusted
incremental indirect cost = $44, p = 0.042). CONCLUSIONS:
SD was associated with a statistically signiﬁcant increase in
health care and work loss costs. The multivariate analysis indi-
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cated that the total direct and indirect cost increase was approx-
imately $106 per person per month.
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FREQUENCY AND COST CONSEQUENCES ASSOCIATED
WITH FAILURE OF MUPIROCIN AMONG UNCOMPLICATED
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OBJECTIVES: To derive the frequency and costs associated with
failure of initial mupirocin therapy among patients diagnosed
with uncomplicated skin and skin structure infections (uSSSI).
METHODS: A retrospective observational analysis was con-
ducted using data obtained from the Integrated Health care
Information Systems (IHCIS) dataset which contains nationally
representative managed care claims data. This analysis utilized
medical, pharmacy, and enrollment records between January 1,
2003 and April 30, 2006. Patients with a mupirocin prescription
and a corresponding ICD9 code for an uSSSI up to 15 days prior
to their index mupirocin prescription were eligible for the analy-
sis. A patient was classiﬁed as failing treatment with mupirocin
if they either: 1) received a second antibiotic commonly used to
treat uSSSI 5–30 days after their index mupirocin prescription
or 2) experienced an uSSSI-related hospitalization within 30 days
after the index mupirocin prescription. Among those patients
that were deﬁned as mupirocin failures the frequency and costs
(2005 US dollars) of a second uSSSI antibiotic, outpatient
encounter, and hospitalization was derived. RESULTS: A total
of 160,445 mupirocin prescriptions associated with an uSSSI
were dispensed during the study timeframe. Of those prescrip-
tions 12,650 (7.0%) resulted in failure. Among failures 93.8%
(11,867) required a second antibiotic contributing a mean cost
of $62 per prescription. Outpatient encounters were required 
by 40.3% (4782) of failures with a mean cost of $221 per
encounter. Only 9.0% of failures required a hospitalization, but
resulted in a mean cost of $6597 per hospitalization. This trans-
lates into an expected cost of $740.95 per mupirocin failure
among uSSSI patients. CONCLUSION: The management of
uSSSI is costly when initial pharmacologic therapy fails.
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OBJECTIVES: The quality of dermatologic care provided by
physician assistants has not been well documented. This study
characterized the use of potentially inappropriate combination
medication clotrimazole/betamethasone diproprionate (a proxy
for potentially inappropriate care) by physician assistants 
compared to dermatologists and primary care physicians.
METHODS: Data obtained from the National Ambulatory
Medical Care Survey (1990–2000) were used to determine prac-
titioner factors associated with a prescription for clotrima-
zole/betamethasone diproprionate. For each visit sampled that
resulted in a dermatologic diagnosis, a patient log was completed
to include demographic data, reasons for patient visits, physician
diagnoses, services provided, and referral practices. For each
year, we assessed patient visits to include twenty highest derma-
tology-related primary ﬁeld diagnoses (using ICD-9 codes) at
which clotrimazole/betamethasone diproprionate was men-
tioned. Practitioners were grouped as dermatologists, dermatol-
ogy PAs, primary care providers, and primary care PAs, other
specialty physicians and other specialty PAs. One-way ANOVA
and multivariate logistic regression analyses using STATA 9.0
were tested the study objectives. RESULTS: PAs, regardless of
specialty, were more than four times as likely (OR: 4.3, 95%CI:
0.7, 25.6) to prescribe clotrimazole/betamethasone diproprion-
ate when they were the sole provider of care compared to when
under direct supervision by a physician (OR: 1.8, 95%CI: 0.4,
8.0). Dermatology PAs prescribed clotrimazole/betamethasone
diproprionate at a rate of 3.8%, compared to the PCP prescrip-
tion rate of 4.9% and the dermatologist prescription rate of
0.2%. The highest rate of clotrimazole/betamethasone dipropri-
onate prescription was seen in PAs practicing under PCPs,
16.9%. CONCLUSION: The quality of dermatologic care pro-
vided by dermatology physician assistants is closer to that of
primary care physicians than that of dermatologists, evidencing
a need for more extensive training for these practitioners.
However, the use of closely supervised PAs may help provide
more accessible and higher quality dermatologic care to all
patients than provided by primary care practitioners.
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OBJECTIVES: To determine the incremental direct health care
and indirect work loss costs experienced by employer-payers for
patients diagnosed with psoriasis (PS). METHODS: A de-
identiﬁed claims database consisting of 5.1 million covered lives
from 31 Fortune 500 self-insured employers over the period
1998–2005 was used. Each PS patient was matched with three
controls based on age and gender. The average monthly direct
health care costs (i.e., medical & pharmaceutical costs) were
computed for the respective groups. For the subset of patients
who were active employees, the indirect costs of lost work time
were calculated for each group, as measured by employer dis-
ability payments and sick leave time multiplied by the employee’s
wage. In addition, a multivariate two-part regression was used
to isolate the cost increase attributable to PS by controlling for
age, gender, year, comorbidities, and organ transplantation.
RESULTS: The univariate analysis showed that the PS patients
(N = 10,325) were associated with higher medical and pharmacy
costs than the control group (N = 30,975) by an average of $156
and $129 per person per month, respectively (medical: $439 vs.
$283, p < 0.0001; pharmacy: $209 vs. $81, p < 0.0001), bring-
ing the total increase in health care costs to $285 per person per
month ($648 vs. $364, p < 0.0001). In the subset of active
employees, the PS group (N = 2527) was associated with a higher
indirect work loss cost of $81 per person per month ($164 vs.
$83, p < 0.0001) than the control group (N = 6573). For each
cost category, a statistically signiﬁcant cost increase for PS
patients was conﬁrmed through the multivariate analysis
(adjusted incremental direct cost = $77, p = 0.024; adjusted
incremental indirect cost = $43, p = 0.022). CONCLUSIONS:
PS was associated with a statistically signiﬁcant increase in health
care and work loss costs. The multivariate analysis indicated that
